← Leaderboards
David Johnson
Corixa Corporation
$22,189,736
Attributed
$22,189,736
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.6M · FY2009–13$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$22,189,736 · 2
By mechanism
N01$22,189,736 · 2
Top collaborators
No co-investigators on record.
Most similar at Corixa Corporation
Same institution · by research overlap
- Jay Evans$13,735,700
- David Alan Johnson$374,959
- Witold Cieplak$2,691,277
Others in their field
Top investigators on “Cell Mediated Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$463,777,552
- Barton F Haynes · Duke University$292,937,245
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$256,655,840
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$154,364,612
- Dan H. Barouch · Fred Hutchinson Cancer Center$90,860,292
- Georgia D Tomaras · Fred Hutchinson Cancer Center$71,993,559
Research focus
Cell Mediated Immune ResponseAntigensImmune SystemInfluenza Virus VaccineBaseTlr4 GeneVaccine EfficacyAdjuvantContractsTlr7 GeneAgonistResearch PersonnelB-LymphocytesT-LymphocytePreclinical TestingImmunologic AdjuvantsPreventLeadLibrariesHigh Throughput ScreeningImmunologic ReceptorsCommunicable DiseasesLymphocytic Choriomeningitis VirusPrograms
Grant awards (6)
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$3,750,387
N01 · FY2013 · AI · contact PI
Adjuvant Development$715,000
N01 · FY2013 · AI · contact PI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$1,078,434
N01 · FY2012 · AI · contact PI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$6,018,893
N01 · FY2011 · AI · contact PI
Adjuvant discovery: lipid A mimetics$8,318,730
N01 · FY2009 · AI · contact PI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$2,308,292
N01 · FY2009 · AI · contact PI